|
|
 |
|
Viewing report
|
|
|
|
Strategic Perspectives 2001: Breast Cancer Cost Analysis
Datamonitor, Feb 2001
Utilizing pricing data amassed from the seven major markets of the US, Japan, Germany, France, Italy, Spain and the UK, this report provides a detailed analysis of the major drug regimes used in the treatment of breast cancer alongside the current pricing and reimbursement status in each of the countries studied. Thus, an intriguing evaluation of the cost of breast cancer treatment is presented. * Plan your investment in pharmacoeconomic studies and patient assistant programs, and intensify links with advocacy groups. * Assess your launch and product lifecycle strategies to remain competitive within the breast cancer market. * Understand how your competitors are differentiating themselves and gaining competitive advantage. * Benchmark your pricing strategies against other breast cancer therapies across the US, Europe, and Japan.
Customers who bought this item also bought
Treatment Algorithms 2001 Breast Cancer: Herceptin Falling into Stride
Drug Targets for Breast Cancer
Drugs of Tommorow 2002: Breast Cancer
Breast Cancer Insight - Defining Drug Decisions - How Can Companies Influence the Treatment of Breast Cancer?
Pipeline Insight: Breast Cancer - Complex Combinations of Old and New?
Stakeholder Insight: The Screening and Diagnosis of Breast Cancer
Breast Cancer Opinion Leader Forum
Stakeholder Insight: Adjunct Therapies in Breast Cancer
|
|
|
|
